Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.
JAMA Surg. 2018 Dec 1;153(12):e183567. doi: 10.1001/jamasurg.2018.3567. Epub 2018 Dec 19.
The nationwide fecal immunochemical test-based screening program has influenced surgical care for patients with colorectal cancer (CRC) in the Netherlands, although these implications have not been studied in much detail so far.
To compare surgical outcomes of patients diagnosed as having CRC through the fecal immunochemical test-based screening program (screen detected) and patients with non-screen-detected CRC.
DESIGN, SETTING, AND PARTICIPANTS: This was a population-based comparative cohort study using the Dutch ColoRectal Audit and analyzed all Dutch hospitals performing CRC resections. Patients who underwent elective resection for CRC between January 2011 to December 2016 were included.
Colorectal cancer surgery.
Postoperative nonsurgical complications, postoperative surgical complications, postoperative 30-day or in-hospital mortality, and complicated course (postoperative complication resulting in a hospital stay >14 days and/or a reintervention and/or mortality). A risk-stratified comparison was made for different postoperative outcomes based on screening status (screen detected vs not screen detected), cancer stage (I-IV), and for cancer stage I to III also on age (aged ≤70 years and >70 years) and American Society of Anesthesiologists score (I-II and III-IV). To determine any residual case-mix-corrected differences in outcomes between patients with screen-detected and non-screen-detected cancer, univariable and multivariable logistic regression analyses were performed.
In total, 36 242 patients with colon cancer and 17 416 patients with rectal cancer were included for analysis. Compared with patients with non-screen-detected CRC, screen-detected patients were younger (mean [SD] age, 68 [5] vs 70 [11] years), more often men (3777 [60%] vs 13 506 [57%]), and had lower American Society of Anesthesiologists score (American Society of Anesthesiologists score III+: 838 [13%] vs 5529 [23%]). Patients with stage I to III colon cancer who were screen detected had a significantly lower mortality and complicated course rate compared with non-screen-detected patients. For patients with rectal cancer, only a significant difference was found in mortality rate in patients with a cancer stage IV disease, which was higher in the screen-detected group. Compared with non-screen-detected colon cancer, an independent association was found for screen-detected colon cancer on nonsurgical complications (adjusted odds ratio, 0.81; 95% CI, 0.73-0.91), surgical complications (adjusted odds ratio, 0.80; 95% CI, 0.72-0.89), and complicated course (adjusted odds ratio, 0.80; 95% CI, 0.71-0.90). Screen-detected rectal cancer had significantly higher odds on mortality.
Postoperative outcomes were significantly better for patients with colon cancer referred through the fecal immunochemical test-based screening program compared with non-screen-detected patients. These differences were not found in patients with rectal cancer. The outcomes of patients with screen-detected colon cancer were still better after an extensive case-mix correction, implying additional underlying factors favoring patients referred for surgery through the screening program.
全国性的粪便免疫化学检测筛查计划已经影响了荷兰结直肠癌(CRC)患者的外科治疗,尽管到目前为止,这些影响还没有被详细研究。
比较通过粪便免疫化学检测筛查计划(筛查发现)诊断为 CRC 的患者和非筛查发现的 CRC 患者的手术结果。
设计、地点和参与者:这是一项基于荷兰 ColoRectal Audit 的人群比较队列研究,分析了所有进行 CRC 切除术的荷兰医院。纳入了 2011 年 1 月至 2016 年 12 月期间接受择期 CRC 切除术的患者。
结直肠癌手术。
术后非手术并发症、术后手术并发症、术后 30 天或住院内死亡率和复杂病程(术后并发症导致住院时间>14 天和/或再次干预和/或死亡)。基于筛查状态(筛查发现与未筛查发现)、癌症分期(I-IV 期)以及癌症分期 I-III 期时的年龄(≤70 岁和>70 岁)和美国麻醉医师协会评分(I-II 和 III-IV),对不同的术后结果进行风险分层比较。为了确定筛查发现和非筛查发现的癌症患者之间在结果上是否存在任何残余病例混杂校正差异,进行了单变量和多变量逻辑回归分析。
共纳入 36242 例结肠癌和 17416 例直肠癌患者进行分析。与非筛查发现的 CRC 患者相比,筛查发现的患者年龄更小(平均[标准差]年龄,68[5]岁 vs 70[11]岁),更多为男性(3777[60%] vs 13506[57%]),美国麻醉医师协会评分较低(美国麻醉医师协会评分 III+:838[13%] vs 5529[23%])。筛查发现的 I 期至 III 期结肠癌患者的死亡率和复杂病程发生率明显低于非筛查发现的患者。对于直肠癌患者,仅在筛查发现的 IV 期癌症患者中发现死亡率存在显著差异,该组死亡率更高。与非筛查发现的结肠癌相比,筛查发现的结肠癌在非手术并发症(调整后的优势比,0.81;95%置信区间,0.73-0.91)、手术并发症(调整后的优势比,0.80;95%置信区间,0.72-0.89)和复杂病程(调整后的优势比,0.80;95%置信区间,0.71-0.90)方面存在独立关联。筛查发现的直肠癌患者的死亡率显著更高。
通过粪便免疫化学检测筛查计划转诊的结肠癌患者的术后结果明显优于非筛查发现的患者。在直肠癌患者中没有发现这些差异。在进行广泛的病例混杂校正后,筛查发现的结肠癌患者的结果仍然更好,这意味着支持通过筛查计划转介手术的患者存在其他潜在因素。